Latch Medical, a Dublin, Ireland-based vaccine and biologics delivery technology company, received an investment from West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration.
The amount of the deal was not disclosed. West, which joins Latch Medical’s existing investors Atlantic Bridge and Enterprise Ireland, will take a minority ownership stake in Latch Medical.
Spun out of University College Dublin by its co-Founders Ronan Byrne and Nicky Bertollo in 2019, Latch has developed Pharma Latch technology, which offers two delivery device platforms that allow for intradermal delivery of vaccines and biologics with rapid, consistent dosing. The technology anchors securely to the skin and uses either hollow or coated microneedles to deliver and disperse vaccine and biologics payloads. The technology can facilitate higher payloads than microneedle technologies developed in the past. It requires minimal training for clinicians to use.
West Pharmaceutical Services is a provider of injectable solutions and services. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2021 generated $2.83 billion in net sales. It is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor’s 500 index.
FinSMEs
13/08/2022